Search company, investor...
Protagonist Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Market Cap


Stock Price


About Protagonist Therapeutics

Protagonist Therapeutics is a biotechnology company pursuing the discovery and development of target oral peptides and new chemical entities (NCEs). It also owns a technology platform aimed at overcoming expanding the scope of peptide therapeutics to address unmet needs. On August 13, 2020, Protagonist Therapeutics was acquired by Techone, terms of the transaction were not disclosed.

Protagonist Therapeutics Headquarters Location

7707 Gateway Boulevard Suite 140

Milpitas, California, 95035,

United States

510 474 0170

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Protagonist Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Protagonist Therapeutics is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

838 items

Protagonist Therapeutics Patents

Protagonist Therapeutics has filed 49 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Monoclonal antibodies
  • Immunology
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Monoclonal antibodies, Transcription factors, Proteins, Immunology


Application Date


Grant Date



Related Topics

Clusters of differentiation, Monoclonal antibodies, Transcription factors, Proteins, Immunology



Latest Protagonist Therapeutics News

New LPAM Protagonist enters IBD story as Morphic pursues phase II

Sep 20, 2022

Sep. 20, 2022 The May 2014 approval of Takeda Pharmaceutical Co. Ltd.’s Entyvio (vedolizumab) brought welcome news in the form of an important mechanism of action for patients with ulcerative colitis and Crohn’s disease, but also means a burdensome course of administration – 30 minutes’ worth of infusion every six weeks, a drawback that other developers are trying to remedy. Standouts among the up-and-comers are Morphic Holding Inc., with an oral candidate that works through the same mechanism of action as Entyvio, and Protagonist Therapeutics Inc.

Protagonist Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Protagonist Therapeutics Rank

  • When was Protagonist Therapeutics founded?

    Protagonist Therapeutics was founded in 2001.

  • Where is Protagonist Therapeutics's headquarters?

    Protagonist Therapeutics's headquarters is located at 7707 Gateway Boulevard, Milpitas.

  • What is Protagonist Therapeutics's latest funding round?

    Protagonist Therapeutics's latest funding round is PIPE.

  • How much did Protagonist Therapeutics raise?

    Protagonist Therapeutics raised a total of $67M.

  • Who are the investors of Protagonist Therapeutics?

    Investors of Protagonist Therapeutics include BVF Partners, Lilly Ventures, Starfish Ventures, Pharmstandard International, Johnson & Johnson Innovation and 8 more.

  • Who are Protagonist Therapeutics's competitors?

    Competitors of Protagonist Therapeutics include Aerogen, Rigel Pharmaceuticals, Actinobac Biomed, Carena, Ikaria and 12 more.

You May Also Like


NeuroKey A/S develops drugs for the critical care segment addressing the need for emergency medication that can increase the survival rate and reduce the risk of lasting neurological damage in critical care patients.

Galleon Pharmaceuticals

Galleon Pharmaceuticals has built a drug discovery and development platform that focuses on the pharmaceutical treatment of sleep apnea and related breathing-control disorders. The company's platform incorporates recent advances in neurobiology, molecular physiology, respiratory medicine and medicinal chemistry. The Company has developed proprietary models of sleep apnea and breathing control that enable a multi-dimensional analysis of the primary causes of sleep apnea and related conditions.

Invistics Logo

Invistics provides cloud-based software solutions and supporting consulting services that help companies achieve the right inventory levels for their supply chain through advanced analytics and actionable insights. The company's demand-driven Lean solutions raise profitability by improving flow and increasing customer satisfaction, while reducing cycle times and costs.


PhenoTech, Inc. was founded in 2003 and funded by BioAdvance in March 2004. PhenoTech was created to develop University of Pennsylvania technology for the discovery, development and commercialization of monoclonal antibodies (mAbs) to be used in blood diagnostic and blood therapeutic applications. The company is in the process of winding down operations.

Ulysses Pharmaceuticals

Ulysses Pharmaceuticals is dedicated to the discovery and development of safe antimicrobial agents for the treatment of severe and recurrent infections occurring in humans. The Company intends to become an industry leader in the antiinfective field through the development of new antibiotics including some acting as Trojan Horses that take advantage of essential microbial transport systems to specifically enter targeted pathogens. Ulysses concentrates on the development of advanced hit and lead compounds with promising features and characteristics that are indicative of potent antibacterial agents with potential for strong market penetration.


Chemopreventia focuses on the development of cancer preventive drugs and works on the mechanism of action of retinoids and other chemopreventive agents in the control of epithelial cancers. The company also focuses on the protein receptors that mediate the action of chemopreventive agents.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.